| アブストラクト | INTRODUCTION: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) places a substantial burden on patients and healthcare systems. The objectives of this study were to describe clinical characteristics and assess healthcare resource utilization and costs of patients with SSc-ILD in England, compared with patients with non-pulmonary organ involvement related to SSc (SSc-OOI). METHODS: This population-based retrospective study used data from the Clinical Practice Research Datalink linked to Hospital Episode Statistics. Data were extracted from medical records dated January 1, 2005 to March 31, 2016. Patients with SSc were identified and placed in subgroups based on organ involvement: SSc-ILD, SSc-OOI, and both (SSc-ILD-OOI). Patients with SSc-ILD-OOI were included in both the SSc-ILD and SSc-OOI subgroups. All-cause healthcare costs, excluding medication costs, were calculated to 2016 British pounds sterling ( pound). RESULTS: This study included 675 patients with SSc: 174 (26%) had neither ILD nor other organ involvement (OOI); 127 (19%) had SSc-ILD; 477 (71%) had SSc-OOI; 103 (15%) had SSc-ILD-OOI. Age-weighted median [interquartile range (IQR)] annual healthcare costs per patient were: pound1496 ( pound664- pound2817) in SSc only; pound6375 ( pound3451- pound15,041) in SSc-ILD; pound4084 ( pound1454- pound10,105) in SSc-OOI; pound6632 ( pound4023- pound17,009) in SSc-ILD-OOI. In multivariate analysis, older age at diagnosis, diagnosis of anemia, and number of comorbid diseases were associated with higher yearly healthcare costs. CONCLUSION: The annual healthcare cost for patients with SSc-ILD is substantial, and higher than that of patients with SSc-OOI or SSc only. These results quantify the economic burden of SSc-ILD in a real-world setting, and highlight the need for treatment of this disease. |
|---|
| ジャーナル名 | Advances in therapy |
|---|
| 投稿日 | 2020/4/23 |
|---|
| 投稿者 | Gayle, Alicia; Schoof, Nils; Alves, Margarida; Clarke, Deborah; Raabe, Christina; Das, Prithwiraj; Del Galdo, Francesco; Maher, Toby M |
|---|
| 組織名 | Boehringer Ingelheim Ltd, Bracknell, UK.;Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.;University of Leeds, Leeds, UK.;Fibrosis Research Group, National Heart and Lung Institute, Imperial College;London, London, UK. t.maher@rbht.nhs.uk.;Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.;t.maher@rbht.nhs.uk. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/32319038/ |
|---|
